The model holds potential for the better integration of TB and ART support.”
“Two new cycloartane-type triterpenoids, 3 beta-hydroxy-21-O-acetyl-24-methylenecycloartane DZNeP order (3) and 3 beta,21-dihydroxy-24,31-epoxy-24-methylenecycloartane (4), one new flavanone, 7-hydroxy-6,8-dimethoxyflavanone (5), two new natural products, 2-hydroxybenzyl benzoate
(7) and 2-phenyl-2-acetoxyethyl benzoate (8), and ten known compounds, 3 beta-hydroxy-24-methylenecycloartane (1), 3 beta,21-dihydroxy-24-methylenecycloartane (2), desmosdumotin B (6), artabotrene (9), (-)-senepoxide (10), (+)-crotepoxide (11), (-)-1,6-desoxypipoxide (12), rotundol (13), cassipourol (14) and (+)-spathulenol (15) were isolated from the leaves of Dasymaschalon dasymaschalum. The structures of the new compounds were elucidated by spectroscopic analysis and of the known compounds by comparison of their physical, UV, IR, H-1 and C-13 NMR data with those of published MEK inhibitor compounds. Antimycobacterial, antiplasmodial and cytotoxic activities of the isolates, except 8 and 10 were evaluated. Compounds 1, 4, 5, 11, 12 and 15 exhibited potent cytotoxic activities against human lung cancer cell lines (NCI-H187) with respective IC50 values of 4.67, 7.82,
1.85, 6.33, 3.07 and 6.68 mg/mL. (C) 2013 Phytochemical Society of Europe. Published by Elsevier B. V. All rights reserved.”
“BACKGROUND: This quasi-experimental cohort study aimed to evaluate World Health Organization (WHO) defined tuberculosis (TB) treatment outcomes for patients under directly observed treatment at a health facility (clinic DOT) or at home (family DOT) in urban Pakistan.
METHODS: We enrolled 582 sputum smear-positive TB patients being selleck products treated by either clinic DOT (n = 295) or family DOT (n = 287) in 11 treatment centres. Patients and/or family members were interviewed for baseline
measurements. WHO-defined treatment outcomes were evaluated at the end of treatment. Proportions of ‘cured’ patients were computed. A log-binomial model was used to evaluate the associations of various factors with ‘cured’ status.
RESULTS: The proportion of ‘cured’ patients was respectively 66% and 34% in the clinic DOT and family DOT groups (risk difference 0.32; 95%CI 0.24-0.39). Patients on clinic DOT were more likely to achieve cure (adjusted relative risk [RR(adj)] 1.85; 95%CI 1.43-2.39) than those on family DOT, as were patients satisfied with their health care worker’s attitude (RR(adj) 5.73; 95%CI 2.54-12.96).
CONCLUSION: Clinic DOT nearly doubled the proportion of cured patients compared to family DOT. Efforts to improve care-provider attitudes to enhance patient satisfaction, and effective implementation of the WHO’s public-private mix approach, may enhance TB control in this and similar settings.